Tempus, a leader in artificial intelligence and precision medicine, today announced that the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers t...
Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test. The test uses a machine learning model to analyze sequence data produced b...
Study aims to create the most robust, multi-omic dataset for patients with NSCLC Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114). The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset...
Diagnostic will be used to prospectively assess HLA loss in patients’ tumors and guide appropriate treatment selection in TScan’s solid tumor clinical trial Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical...
Tempus, a leader in artificial intelligence and precision medicine, today introduces its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII. Tempus has always understood the importa...
Tempus, a leader in artificial intelligence and precision medicine, today announced the company will exhibit 20 abstracts at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting, which convenes from June 2-6, in Chicago, Illinois. This year, Tempus is presenting its latest research via two oral presentations, one poster discussion session, and...
AI-enabled clinical assistant provides access to patient insights directly at your fingertips Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced the upcoming broad launch of Tempus One – the first, AI-enabled clinical assistant that leverages advancements in generative AI to provide clinicians access to patient insights directly at...
Tempus, a leader in artificial intelligence and precision medicine, today announced that Norman E. “Ned” Sharpless, MD, will serve as a senior strategic advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and cancer researcher to further the company’s mission...
Tempus, a leader in artificial intelligence and precision medicine, today announced that Ezra Cohen, MD is joining the company as its Chief Medical Officer of Oncology. Dr. Cohen is helping oversee Tempus’ medical operations, with a primary focus on oncology and the company’s patient and provider offerings....
xT CDx is the company’s first Premarket Approval from the FDA Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx. xT...
